PMID- 27509208 OWN - NLM STAT- MEDLINE DCOM- 20170822 LR - 20220129 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 8 DP - 2016 TI - Netrin-1 Reduces Monocyte and Macrophage Chemotaxis towards the Complement Component C5a. PG - e0160685 LID - 10.1371/journal.pone.0160685 [doi] LID - e0160685 AB - Netrin-1, acting at its cognate receptor UNC5b, has been previously demonstrated to inhibit CC chemokine-induced immune cell migration. In line with this, we found that netrin-1 was able to inhibit CCL2-induced migration of bone marrow derived macrophages (BMDMs). However, whether netrin-1 is capable of inhibiting chemotaxis to a broader range of chemoattractants remains largely unexplored. As our initial experiments demonstrated that RAW264.7 and BMDMs expressed high levels of C5a receptor 1 (C5aR1) on their surface, we aimed to determine the effect of netrin-1 exposure on monocyte/macrophage cell migration induced by C5a, a complement peptide that plays a major role in multiple inflammatory pathologies. Treatment of RAW264.7 macrophages, BMDMs and human monocytes with netrin-1 inhibited their chemotaxis towards C5a, as measured using two different real-time methods. This inhibitory effect was found to be dependent on netrin-1 receptor signalling, as an UNC5b blocking antibody was able to reverse netrin-1 inhibition of C5a induced BMDM migration. Treatment of BMDMs with netrin-1 had no effect on C5aR1 proximal signalling events, as surface C5aR1 expression, internalisation and intracellular Ca2+ release following C5aR1 ligation remained unaffected after netrin-1 exposure. We next examined receptor distal events that occur following C5aR1 activation, but found that netrin-1 was unable to inhibit C5a induced phosphorylation of ERK1/2, Akt and p38, pathways important for cellular migration. Furthermore, netrin-1 treatment had no effect on BMDM cytoskeletal rearrangement following C5a stimulation as determined by microscopy and real-time electrical impedance sensing. Taken together these data highlight that netrin-1 inhibits monocyte and macrophage cell migration, but that the mechanism behind this effect remains unresolved. Nevertheless, netrin-1 and its cognate receptors warrant further investigation as they may represent a potential avenue for the development of novel anti-inflammatory therapeutics. FAU - Taylor, Lewis AU - Taylor L AUID- ORCID: 0000-0003-4622-9890 AD - Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. FAU - Brodermann, Maximillian Hugo AU - Brodermann MH AD - Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. FAU - McCaffary, David AU - McCaffary D AD - Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. FAU - Iqbal, Asif Jilani AU - Iqbal AJ AD - Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. FAU - Greaves, David R AU - Greaves DR AD - Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom. LA - eng GR - RG/15/10/31485/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20160810 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (C5ar1 protein, mouse) RN - 0 (Ccl2 protein, mouse) RN - 0 (Chemokine CCL2) RN - 0 (Immunologic Factors) RN - 0 (NTN1 protein, human) RN - 0 (Nerve Growth Factors) RN - 0 (Ntn1 protein, mouse) RN - 0 (Receptor, Anaphylatoxin C5a) RN - 0 (Tumor Suppressor Proteins) RN - 158651-98-0 (Netrin-1) RN - 80295-54-1 (Complement C5a) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Calcium/metabolism MH - Cell Line MH - Chemokine CCL2/genetics/metabolism MH - Chemotaxis/drug effects/*physiology MH - Complement C5a/*metabolism MH - Humans MH - Immunologic Factors/pharmacology MH - Macrophages/drug effects/*physiology MH - Male MH - Mice, Inbred C57BL MH - Monocytes/drug effects/physiology MH - Nerve Growth Factors/chemistry/metabolism/*pharmacology MH - Netrin-1 MH - Phosphatidylinositol 3-Kinases/metabolism MH - Receptor, Anaphylatoxin C5a/metabolism MH - Signal Transduction/drug effects MH - Tumor Suppressor Proteins/chemistry/metabolism/*pharmacology PMC - PMC4980032 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2016/08/11 06:00 MHDA- 2017/08/23 06:00 PMCR- 2016/08/10 CRDT- 2016/08/11 06:00 PHST- 2016/04/05 00:00 [received] PHST- 2016/07/24 00:00 [accepted] PHST- 2016/08/11 06:00 [entrez] PHST- 2016/08/11 06:00 [pubmed] PHST- 2017/08/23 06:00 [medline] PHST- 2016/08/10 00:00 [pmc-release] AID - PONE-D-16-13727 [pii] AID - 10.1371/journal.pone.0160685 [doi] PST - epublish SO - PLoS One. 2016 Aug 10;11(8):e0160685. doi: 10.1371/journal.pone.0160685. eCollection 2016.